This review discusses the future role of pharmacogenomics in the treatment of Alzheimer’s disease, and current opportunities.
Striving for ‘best health’: driving up the standard of services for Parkinson’s disease patients in the UK
Neurology Central talks to David Burn, Clinical Director at Parkinson’s UK, to discuss the recently launched Parkinson’s Excellence Network, and the future of Parkinson’s disease treatment and care in the UK.
Stereotactic radiosurgery for brain metastases and the questionable role of whole-brain radiotherapy
In this exclusive webinar, Oncology Central Ambassador Arjun Sahgal from Sunnybrook Health Sciences Centre (ON,…
The use of opioids for both benign and cancer-related chronic pain has increased exponentially over…
This commentary discusses the role of epigenomics in the neurodegeneration of ataxia-telangiectasia
This review summarizes the current knowledge and progress in epigenetic research in chronic pain and discusses the potential role of epigenetic modifications as therapeutic antinociceptive targets in this disorder.
This review examines the research efforts that have focused on the role and therapeutic targeting of α-, β- and γ-secretase in Alzheimer’s disease
Background: Conventional and PEGylated liposomes were developed, aimed at improving the pain-killing effect of opiorphin.…
Long-term care characteristics that influence the utility and effectiveness of nonpharmacological therapies for people with dementia
Political, economic and organizational factors shape requirements for long-term aged care (LTC) serving people with…
This review is a concise summary of nonmotor symptoms in both genetic and idiopathic Parkinson’s disease patients, highlighting the importance of nonmotor symptoms in research and clinical practice of Parkinson’s disease together with some of the potential differences in pathophysiology and clinical features.